George Maliha M.D.

GEORGE MALIHA focuses his practice on healthcare and FDA regulatory, compliance, and transactional matters for a wide range of life sciences and healthcare provider clients. He provides strategic, day-to-day counsel on fraud and abuse issues involving the federal Anti-Kickback Statute, Eliminating Kickbacks in Recovery Act, the federal physician “Stark” Law, and the False Claims Act. George also advises clients on the Inflation Reduction Act, the Sunshine Act, Medicare and Medicaid coverage and reimbursement, 340B program, government price reporting laws, market access, patient assistance programs, as well as the development and implementation of healthcare compliance programs.

Prior to joining Sidley, George was a resident in internal medicine at the Hospital of the University of Pennsylvania, where he researched the legal implications of AI in healthcare and dialysis payment policy. He is board certified in internal medicine.

George earned his law degree, magna cum laude, from Harvard Law School. While attending law school, he served as co-editor-in-chief of the Harvard Journal on Legislation and director of projects for the Harvard Law and Entrepreneurship Project. George earned his M.D., Alpha Omega Alpha, from the Perelman School of Medicine at the University of Pennsylvania. He received his A.B., summa cum laude, in molecular biology with a minor in public policy from Princeton University.

• Prospect Medical Holdings, Inc. (Prospect) and several of its subsidiaries in its Chapter 11 cases in the United States Bankruptcy Court for the Northern District of Texas. With over US$2.3 billion in outstanding funded debt, Prospect’s Chapter 11 cases are among the largest filed in 2025.
• GIC in connection with the US$18.3 billion take-private acquisition of Hologic, Inc., a medical diagnostics and imaging company specializing in women's health (pending).
• Lumexa Imaging Holdings, Inc. in its US$462.5 million initial public offering of common stock.
• BDT & MSD Partners in connection with their AU$1.6 billion investment in DBG Health, a leading Australian beauty and pharmaceutical company.